New to The Street’s TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company’s FDA Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 94% success with no reinfections. In treated patients, the microbiome bacteria found in the digestive tract shows the bacteria maintaining and restoring itself within those patients after a 10-day treatment. At a recent microbiome conference presentation in Texas, the Company compared logarithmic results from a competitor drug (vancomycin) to that of its Ibezapolstat drug, showing the differences in the effects on gut microbiome bacteria. Competitor drugs have been used for decades to treat CDI, but the reinfection rates are very high and greatly diminished gut microbiome bacteria. ACXP’s Ibezapolstat study results have shown to combat reinfections effectively. Based on the data and other publications regarding the market size for newly discovered and effective treatment of CDI, ACXP believes Ibezapolstat could be a market worth over $1B. Decades-old antibacterial drugs are not working due to changes in the molecular composition of CDI. Thousands of people worldwide die annually, with many catching CDI in hospitals and nursing homes. Acurx Pharmaceuticals, Inc. believes its Ibezapolstat drug is the next generation for effectively treating CDI. Throughout 2024, Investors and others should expect more exciting news about Ibezapolstat and other positive corporate ongoings. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc.. – https://www.acurxpharma.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list